Aller au contenu
Retour à la recherche

NCT07527468Pas encore en recrutement

HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving Surgery

Résumé

This study evaluates whether systematic intraoperative margin assessment using the Histolog® Scanner - a confocal fluorescence microscopy device - reduces the need for reoperation after breast-conserving surgery (lumpectomy) in women with lobular carcinoma (ILC), ductal carcinoma in situ (DCIS), or invasive carcinoma with a DCIS component (NST+DCIS). After lumpectomy, the fresh specimen is imaged in real time by the surgeon using the Histolog® Scanner, which produces histological-quality images of the specimen surface without any tissue processing. This allows immediate assessment of surgical margins in the operating room, enabling the surgeon to perform additional tissue removal if needed before closing. Based on institutional data from 266 cases at CHVR (2021-2024), the current reoperation rate in this population is 11.3%. The study tests whether systematic use of the Histolog® Scanner in addition to standard care reduces this rate by 50% or more (to ≤5.6%). A total of 228 patients will be enrolled prospectively at the Centre Hospitalier du Valais Romand (CHVR), Sion, Switzerland. The reoperation decision is made by the multidisciplinary tumour board based on final histopathology results, independently of the intraoperative findings.

Critères d'éligibilité

1. Female patient, aged 18 years or older at time of surgery. 2. Pre-operative core needle biopsy (CNB) or vacuum-assisted biopsy (VAB) with histological diagnosis of one of the following: 1. invasive lobular carcinoma (ILC/CLI), 2. pure ductal carcinoma in situ (DCIS), or 3. invasive carcinoma of non-special type (NST) with an associated DCIS component. 3. Planned breast-conserving surgery (BCS / lumpectomy) at CHVR. 4. Signed electronic informed consent (eIC) obtained prior to any study procedure. Exclusion Criteria: 1. Pregnancy (confirmed or suspected) at time of surgery. 2. Prior neo-adjuvant treatment (hormonal therapy or chemotherapy) for the current breast cancer diagnosis. 3. Surgical indication for mastectomy rather than BCS. 4. Known hypersensitivity or allergy to acriflavine (fluorescent staining agent used with the Histolog Scanner). 5. Incapacity to provide informed consent. 6. Previous enrolment in this study.

Contacts

Les coordonnées de l'équipe de l'essai s'affichent sur demande.

Voir la fiche officielle de l'essai
Statut
Pas encore en recrutement
Phase
Sans phase (N/A)
Type d'étude
Interventionnelle
Pays
Suisse
Promoteur
Hôpital du Valais(Autre)
N° de protocole
HISMAR-CHVR-2025
Pathologies
Breast Cancer, Ductal Carcinoma In Situ, Invasive Lobular Carcinoma, Breast Neoplasm Female
Interventions
Dispositif

Traitements évalués

  • Histolog® Scanner

Collaborateurs

SamanTree Medical SA

Lieux · 1

  • Sion, SuisseCentre Hospitalier du Valais Romand (CHVR)Recrutement pas encore ouvert dans ce centre

Au total, dans le monde, le seul centre listé au registre est prévu ; le recrutement n'est pas encore ouvert.

Statut par centre selon le registre ClinicalTrials.gov (dernière mise à jour publiée : 14 avril 2026).

Ce statut peut avoir changé et ne dit rien de votre éligibilité : avant toute démarche, vérifiez avec votre oncologue ou le centre.

Autres versions

Ces résultats sont indicatifs et ne remplacent pas un avis médical — à discuter avec votre médecin.